The collaboration highlights two essential components necessary for the successful recovery of empty and full AAV capsids during anion-exchange (AEX) purification
Alpha Teknova and Sartorius BIA Separations, part of life science group Sartorius, have announced the companies have entered into a collaboration arrangement that will help gene therapy companies streamline the downstream purification process.
The collaboration highlights two essential components necessary for the successful recovery of empty and full AAV capsids during anion-exchange (AEX) purification: the separation technology and the buffer composition. With Sartorius BIA Separation’s proprietary AAV platform designed to optimise the separation of viral particles, and Teknova’s custom, high-quality buffer solutions developed to maximise capsid enrichment, the companies conducted a robust design of experiment (DOE) and successfully created a screening kit with optimised buffer formulations that drive consistency and increased purity when paired with the BIA CIMmultus QA monolith.
Through our collaboration, we’re finding new tools to help our customers streamline the development of AAV therapies
“We’re thrilled to find a like-minded partner with Sartorius BIA Separations, a well-respected, global leader in monolith-based technologies who shares our vision of making solutions possible,” said Stephen Gunstream, Teknova’s President and Chief Executive Officer. “Through our collaboration, we’re finding new tools to help our customers streamline the development of AAV therapies by optimising their purification process and increasing the yield and purity of their AAV product.”
“Teknova is the perfect partner for us as we explore robust, end-to-end solutions for our gene therapy customers seeking to achieve better results in the separation and analysis of viral particles,” added Aleš Štrancar, Managing Director at Sartorius BIA Separations. “Based on their ability to quickly manufacture high-quality, custom buffers that are consistent from batch to batch, we’ve been able to reliably reproduce results and confidently target the discreet differences in empty and full AAV particles.”
Gene therapy companies focusing on AAV will be able to get all the required consumables and a protocol that will streamline and accelerate the downstream processing workflow, enabling them to discover novel breakthroughs faster. Teknova and Sartorius BIA Separations intend to continue developing data demonstrating improvements in AAV purification when using their combined methods.